H.C. Wainwright analyst Edward White maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report) today and set a price target of $12.00. The company’s shares closed last Monday at $3.80, close to its 52-week low of $3.21.
According to TipRanks.com, White is a 5-star analyst with an average return of 24.2% and a 43.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
Currently, the analyst consensus on TRACON Pharmaceuticals is a Strong Buy with an average price target of $12.50.
See today’s analyst top recommended stocks >>
TRACON Pharmaceuticals’ market cap is currently $73.25M and has a P/E ratio of -2.60. The company has a Price to Book ratio of 6.15.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TCON in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Read More on TCON:
- Cleveland-Cliffs Acquires Ferrous Processing and Trading Company for $775M
- AbbVie Stock: Price Seems Fair for Biopharmaceutical Play
- Southwest Airlines Cancels More than 1,800 Flights; Shares Plunge
- Apple to Build New Regional HQ in Los Angeles – Report
- Repare Therapeutics (RPTX) Gets a Buy Rating from Bloom Burton
